Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-07-03
2007-07-03
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C540S586000, C540S543000
Reexamination Certificate
active
10440914
ABSTRACT:
The invention is directed to nonpeptide substituted benzodiazepines of Formula I,wherein A, X, n, R1, R2, R3, R4, R5, a and b are as described in the specification, which are useful as vasopressin receptor antagonists for treating conditions associated with vasopressin receptor activity such as those involving increased vascular resistance and cardiac insufficiency. Pharmaceutical compositions comprising a compound of Formula I and methods of treating conditions such as hypertension, congestive heart failure, cardiac insufficiency, coronary vasospasm, cardiac ischemia, liver cirrhosis, renal vasospasm, renal failure, cerebral edema and ischemia, stroke, thrombosis, or water retention are also disclosed.
REFERENCES:
patent: 4617302 (1986-10-01), Robertson
patent: 5663431 (1997-09-01), Di Malta et al.
patent: 5686624 (1997-11-01), Di Malta et al.
patent: 5726322 (1998-03-01), Di Malta et al.
patent: 5728723 (1998-03-01), Di Malta et al.
patent: 5849780 (1998-12-01), DiMalta et al.
patent: 0 636 608 (1995-02-01), None
patent: 0640592 (1995-03-01), None
patent: WO 91 05549 (1991-05-01), None
patent: WO 9407496 (1994-04-01), None
patent: WO 9525443 (1995-09-01), None
patent: WO 9749707 (1997-12-01), None
patent: WO 99 37637 (1999-07-01), None
Ohkawa, T. et al., “Synthesis and Characterization of Orally Active Nonpeptide Vasopressin V2 Receptor Antagonists” 1999, Chem. Pharm. Bull. 47(4) pp. 501-503, Pharmaceutical Society of Japan.
Ashwell, M.A., et al., “The Design, Synthesis and Physico-chemical Properties of a Novel Series of Human Vasopressin V2Receptor Antagonists”,Wyeth-Ayerst Research, Princeton, New Jersey, 2000.
Dusza, J. P., et al., “Way-VNA-932: The First Orally Active, Nonpeptide, Vasopressin V2-Receptor Selective Agonist”,Wyeth-Ayerst Research, Princeton, New Jersey, (Dated not available).
Shumsky, J. S., et al., “Pyridobenzodiazepines: Synthesis and Structure-Activity Relationships of a Novel Class of Orally Active Vasepressin V2Receptor”,Chemical Sciences Wyeth-Ayerst Research, Princeton, N.J. (Date not available).
Shimada, Y., et al., “4,4-Difluoro-5-Methylene-2,3,4,5-Tetrahyro-1H-1-Benzazepine Derivatives: Highly Potent and Selective Antagonist of Arginine Vasopressin V1A Receptor”, Japan Pharmaceutical Co., Ltd., Japan. (Date not available).
Kazumi, K., et al., “7-Chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoyl-amino)benzoyl]-2,3,4,5-tetrahydro-1H-1-benzazepine (OPC-41061); A Potent, Orally Active Nonpeptide Arginine Vasopressin V2Receptor Antagonist”,Bioorganic & Medicinal Chemistry 7, 1999, pp. 1743-1754, second Tokushima Institute of New Drug Research, Otsuka Pharmaceutical Co., Ltd., Japan.
Matschisa, A. et al., “Nonpetide Arginine Vasopressin Antagonists for Both V1Aand V2Receptor: Synthesis and Pharmacological Properties of 4'-[5-(Substituted Methylidene)-2,3,4,5,-tetrahydro-1H-1-benzoazepine-1-carbonyl]benzanilide and 4'-[5-(Substituted Methyl)-2,3-dihydro-1H-1-benzoazepine-1-carbonyl]benzanilide Derivatives”, Pharmaceutical Society of Japan 1999,Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., Japan.
Albright D. J., et al., 5-Fluoro-2omethyl0N-[4-(5H-pyrrolo2,1-c-1,4] benzodiazepine-10(11H)-ylcarbonyl)-3-Orally Active Arginine Vasopressin Antagonist with Selectivity for V2Receptor,J. Med. Chem., 1998, 41, pp. 2442-2444, American Chemical Society.
Kondo K., et al., “Novel Design of Nonpeptide AVP V2Receptor Agonists: Structural Requirements for an Agonist Having 1-(4-Aminobenzoyl)-2,3,4,5-tetrahydro-1H-1-benzazepine as a Template”,J. Med. Chem., 2000, 43, pp. 4388-4397, American Chemical Society.
Yatsu, T., et al., “Pharmacological Profile of YM087, a novel nonpeptide dual vasopresin V1Aand V2receptor Antagonists, in dogs”,European Journal of Pharmacology, 1997, 21, pp. 225-230, Elsevier Science B.V.
Yamamura. Y., et al., “OPC-41061, a Highly Potent Human Vasopressin V2-Recepetor Antagonist: Pharmacologicl Profile Aquaretic Effect by Single and Multiple Oral Dosing in Rats”,The Journal of Pharmacology and Experimental Therapeutics, 1998, vol. 287, No. 3, pp. 860-867, Second Tokushima Institute of New Drug Research et al., Japan.
Venkatesan H., et al., Total synthesis of SR 121463 A, a highly Potent and Selective Vasopressin V2 Receptor Antagonist,The Journal of Organic Chemistry, 2001, vol. 66, No. 11, pp. 3653-3661, American Chemical Society.
Chen Robert H. K.
Xiang Min A.
Coletti Ellen Ciombrone
McKown Jeremy K.
Ortho-McNeil Pharmaceutical , Inc.
Shen Evelyn D.
LandOfFree
Nonpeptide substituted spirobenzoazepines as vasopressin... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nonpeptide substituted spirobenzoazepines as vasopressin..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nonpeptide substituted spirobenzoazepines as vasopressin... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3778690